People: Biomarin Pharmaceutical Inc (BMRN.O)

BMRN.O on Nasdaq

62.08USD
23 Jul 2014
Price Change (% chg)

$1.70 (+2.82%)
Prev Close
$60.38
Open
$61.48
Day's High
$63.05
Day's Low
$60.16
Volume
1,376,160
Avg. Vol
1,300,800
52-wk High
$84.25
52-wk Low
$55.04

Search Stocks

Lawlis, V. Bryan 

Brief Biography

Dr. V. Bryan Lawlis, Ph.D., is an Independent Director of Biomarin Pharmaceutical Inc. Since August 2011 he has served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a privately held limited liability holding company which has held the assets of Itero Biopharmaceuticals, Inc. since August 2011. Prior to serving as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation, a pharmaceutical company, from August 2004, and served on its Board of Directors from February 2005, continuing in both capacities until August 2006. Dr. Lawlis served as Aradigm Corporation’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company and Genentech, Inc. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University. In addition to BioMarin Pharmaceutical Inc., Dr. Lawlis holds board positions on two privately held companies, Itero Biopharmaceuticals, LLC. and Sutro Biopharma, Inc. and in March 2012 was appointed to the board of Geron Corporation, a public biopharmaceutical company.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Pierre Lapalme

--

Jean-Jacques Bienaime

11,364,000

Daniel Spiegelman

4,029,290

Jeff Ajer

2,657,540

Robert Baffi

3,645,440

Henry Fuchs

4,825,470
As Of 30 Dec 2013
Search Stocks